The FDA has approved Cabometyx for some patients 12 years old and older with previously treated neuroendocrine tumors.

"The characteristics of NET vary widely from patient to patient, and very few treatment options ... the Gastrointestinal Cancer Center and Director of the Program in Carcinoid and Neuroendocrine ...

The FDA has approved Cabometyx (cabozantinib) for previously treated, unresectable, locally advanced or metastatic, well-differentiated neuroendocrine tumors.

In the space of a month, I went from working full time as a lecturer, having an active social life, exercising and trying my ...

The treatment of carcinoid syndrome usually involves treating the underlying cancer. But because most of these tumors don't cause carcinoid syndrome until they are advanced, the cancer may be ...

Cabozantinib, an oral tyrosine kinase inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment ... cancer center and director of the program in carcinoid ...

nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Crinetics is also developing atumelnant, an investigational, ...

nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Crinetics is also developing atumelnant, an investigational, ...

The treatment of carcinoid syndrome usually involves treating the underlying cancer. But because most of these tumors don't cause carcinoid syndrome until they are advanced, the cancer may be ...